For The First Time, A Glioma - Brain Cancer - May Be Eliminated By A Chinese Research/medical Team,

< BACK TO INTERNATIONAL starstarstarstarstar   Culture - International Press Release
17th December 2009, 10:18am - Views: 735





Culture International Cellonis Biotechnologies 1 image

Culture International Cellonis Biotechnologies 2 image










MEDIA RELEASE PR37626


For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team,

Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing


BEIJING, Dec. 17 /PRNewswire-Asia-AsiaNet/ --


Using a novel stem cell based technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical team

may eliminate a glioma -- brain cancer -- of a 36 year old Norwegian patient in a hospital in Beijing. The treatment

shows that the activated immune system can directly kill tumor stem cells as well as cancer daughter cells. The

amazing outcome of this novel treatment within a Comprehensive Cancer Therapy tells Cellonis that the future

vaccination therapies may be targeted towards cancer stem cell lysates to improve the antigen-presenting Dendritic

Cell response.


    (Photo: http://www.newscom.com/cgi-bin/prnh/20091217/CNTH007)


    Arve Johnsen, 36, from Norway, a patient diagnosed with glioma in 2006 and relapsed in 2009 after surgical

resection. He arrived in Beijing in August 2009 with his wife Vanja and a one-year-old daughter, with the hope that

the doctors in Norway were wrong. They told the family there is no other option anymore in the Scandinavian

countries or in Europe for Arve to control the progress of disease and prolong his life. Driven by the hope that their

daughter could grow up with a father, the Johnsen family started a research campaign to find other treatments

worldwide, to give Arve a new hope.


    Comprehensive Cancer Therapy in China 


    The Johnsen's, having heard about the sustainable success of a Comprehensive Cancer Therapy (CCT) in

China, decided to try for this last chance in a country 10,000 km away from Norway. This kind of CCT had been

developed in the past few years by a Chinese team of scientific researchers and clinical doctors in Beijing,

combining conventional cancer treatments with Traditional Chinese Medicine (TCM) and cell therapies.


    The role of cancer stem cells in the tumors


    Scientists previously believed that tumors are lumps of cancer tissue that must be completely removed or

destroyed to cure a patient. But over the past few years, researchers have learned that cancer stem cells (CSCs),

comprising a small population of cells, appear to be responsible for the initiation, upkeep and relapse of malignant

tumors. Even if a tumor is almost completely obliterated, it will regenerate from the surviving CSCs and become

even more resistant to treatment than before. 


    Current therapies, including cell therapy, generally do not target CSCs. This allows CSCs to survive until after

chemotherapy or radiation treatments. Killing those cells is a promising strategy to eliminate tumors and prevent

them from re-growing. 


    Prof. Lily Shum: Perfect integration of stem cells and immunotherapies


    "The CSCs may explain why common treatments, particularly chemotherapy, are not sufficient to kill tumors. In

fact, despite the continuous development of new chemotherapeutic agents, brain tumors can develop and remain

resistant to those therapies. The integration of stem cells and immune technologies seems to give us a chance to

find out a new way to target at CSCs," says Prof. Lily Shum, PhD, the chief scientist of Cellonis. 


    "The difficult issue in our project is how to capture and classify CSCs. With our patented technologies, we are

able to isolate the CSCs from patient's brain tumor tissues, culture them and induce the multi-drug and radiation

resistance. These cells possess very strong carcinogenicity, self-renewal, and also a very strong drug and radiation

resistance."


    Lily Shum adds, "The Dendritic Cell (DC) is a very useful tool to conduct a specific immune response against

brain CSCs."  As we know, DC is an antigen-presenting cell that stimulates the innate immune system, as a

Culture International Cellonis Biotechnologies 3 image

messenger, it transfers "the information of cancer cell - antigen" to "the killers of the immune system - the T cells,"

and then T cells can recognize and lyse cells bearing those antigens. "We educate the DC with the brain CSCs,

and then conduct the specific immune response which targets the CSCs." 


    Dr. Dinggang Li: Comprehensive Cancer Therapies


    "The outcome of the first pilot study with Johnsen is amazing. The PET-CT scan for Johnsen shows that all the

tumor disappeared after the treatment," says Dr. Dinggang Li, M.D. PhD. He has developed and conducted CCT

for more than 100 international cancer patients in the past few years. DCs loaded with different kinds of brain

cancer related antigens that target cancer cells and the CIK cell treatment are the main elements of his

comprehensive treatment for cancer. "In the first cycle of treatment, we treated him with comprehensive

approaches including SHG-44 loading DC, CIK cell therapy and TCM, but we had not been able to control the

progression of the disease, the tumors continued to grow. We gave him the DC therapy which targets brain CSCs

in the 2nd cycle of treatment, and it showed a very promising response." 


    Dr. Cindy HAO: More clinical trials to confirm the outcome


    Cindy HAO, M.D., CEO of Cellonis Biotechnologies is optimistic for the future of this new brain cancer approach.

"It gives us a strong confidence to make more efforts toward this direction. This pilot treatment study shows us that

the activated immune system can directly kill tumor stem cells as well as tumor daughter cells. But first of all we

need to extend our further clinical trials to confirm the outcome. And it also tells us that the future vaccination

therapies may be targeted toward Cancer Stem Cell Lysates to improve the antigen-presenting DC response." 


    For more information, please contact:


     Urs. J. Lienert, M.B.A.

     Director International

     Cellonis Biotechnologies Co., Ltd.

     Floor 7, Huizhong Science & Technology Center

     No 1, Shangdi Seventh Road

     Haidian District Beijing, 100085 

     P.R. China

     Email: urs.lienert@cellonis.com; Lienert.Cellonis@yahoo.com

     Phone: +86-10-6296-2795; Cell: +86-150-1054-7487 

     Cell:  +41-76-584-87-60 (Switzerland) 

            (from 20 December 2009 to 15 January 2010)


SOURCE: Cellonis Biotechnologies



To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article